IR Banner

Press Releases

Date Title and Summary Additional Format
Jul 12, 2023
Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
AUSTIN, Texas , July 12, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company’s President & Chief Scientific Officer,
Jun 28, 2023
Lumos Pharma Announces Departure of Chief Medical Officer
AUSTIN, Texas , June 28, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that Chief Medical Officer (CMO) Dr.
Jun 21, 2023
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar
Webinar to Review Data Demonstrating Potential Drug Effect and Durable Response Webinar to be held Today June 21, 2023 at 11:00 AM Eastern Time AUSTIN, Texas , June 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for
May 31, 2023
Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference
AUSTIN, Texas , May 31, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 2023 BIO
May 25, 2023
Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st
KOL Webinar to be held June 21, 2023 at 11:00 AM Eastern Time AUSTIN, Texas , May 25, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical
May 22, 2023
Lumos Pharma to Participate in World Orphan Drug Congress USA
AUSTIN, Texas , May 22, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that management will participate in
May 8, 2023
Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)
Oral and Poster Presentations on OraGrowtH Trials at PES 2023 Further Support Potential for LUM-201 as First Oral Treatment for Moderate Idiopathic PGHD OraGrowtH212 Interim Data Demonstrate LUM-201 Amplifies Natural Pulsatile GH-Secretion and that IGF-1 SDS and Serum Concentrations Remain within
May 3, 2023
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
-- Patient Enrollment Completed in both Phase 2 OraGrowtH Trials -- -- Primary Outcome Data for both OraGrowtH Trials Expected 4Q 2023 -- -- Interim Data from OraGrowtH Trials Accepted for Presentation at PES 2023 – -- Conference Call Scheduled for Today at 4:30pm ET -- AUSTIN, Texas , May 03, 2023
Apr 27, 2023
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
Oral Presentation on Growth Response to LUM-201 Treatment from OraGrowtH210 Trial Interim Data from OraGrowtH212 Trial Highlighted in Poster Presentation AUSTIN, Texas , April 27, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic
Apr 19, 2023
Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
AUSTIN, Texas , April 19, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its first quarter 2023 financial results
Displaying 11 - 20 of 92